On February 15, 2022 Bristol-Myers Squibb Company (NYSE:BMY) reported that it has priced a public offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $6 billion (collectively, the "Notes") (Press release, Bristol-Myers Squibb, FEB 15, 2022, View Source [SID1234608163]). The Notes will be issued in four tranches: (i) $1,750,000,000 in aggregate principal amount of 2.950% notes due 2032, (ii) $1,250,000,000 in aggregate principal amount of 3.550% notes due 2042, (iii) $2,000,000,000 in aggregate principal amount of 3.700% notes due 2052, and (iv) $1,000,000,000 in aggregate principal amount of 3.900% notes due 2062. Bristol Myers Squibb expects that the closing of the Offering will occur on March 2, 2022, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Concurrently with this offering, we commenced a tender offer (the "Tender Offer") to purchase, for cash, various series of our outstanding notes (the "Tender Offer Notes"). We intend to use the net proceeds of this offering (i) to fund the Tender Offer, (ii) to pay fees and expenses in connection therewith and this Offering, (iii) to fund the repayment of outstanding debt upon maturity or earlier redemption and (iv) to the extent of any remaining proceeds, for general corporate purposes. This offering is not contingent on the consummation of the Tender Offer or the purchase of any of the Tender Offer Notes in connection therewith.

BofA Securities, Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, and Wells Fargo Securities, LLC are acting as joint book-running managers for the Offering.

The Offering of the Notes is being made pursuant to an effective shelf registration statement (including a prospectus and preliminary prospectus supplement) (File No. 333-261623) filed with the U.S. Securities and Exchange Commission (the "SEC"). You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Bristol Myers Squibb, any underwriter or any dealer participating in the Offering will arrange to send you the prospectus and the preliminary prospectus supplement (or, if available, the prospectus supplement) if you request it by contacting Bristol Myers Squibb Investor Relations or BofA Securities, Inc. at Attn: Prospectus Department, 200 North College Street, 3rd floor, Charlotte, North Carolina 28255-0001, by email at [email protected] or by telephone at 1-800-294-1322, Deutsche Bank Securities Inc. at Attn: Prospectus Department, 60 Wall Street, New York, New York 10005, by email at [email protected] or by telephone at 1-800-503-4611, Goldman Sachs & Co. LLC at Attn: Prospectus Department, 200 West Street, New York, New York 10282-2198, by email at [email protected], or by telephone at 1-866-471-2526, or Wells Fargo Securities, LLC at Attn: WFS Customer Service, 608 2nd Avenue South, Suite 1000, Minneapolis, Minnesota 55402, by email at [email protected], or by telephone at 1-800-645-3751.

This press release shall not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, the Notes or any other security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

On February 15, 2022 ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health reported an abstract comparing concurrent measures using ImpediMed’s SOZO Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing bone mineral content in cancer patients was accepted for poster presentation at the 39th Annual Miami Breast Cancer Conference on 3-6 March 2022 in Miami Beach, Florida, USA (Press release, ImpediMed, FEB 15, 2022, View Source [SID1234608159]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled, "The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device," analyzes data collected using both SOZO and DXA in healthy participants and cancer patients.

The Miami Breast Cancer Conference draws the multidisciplinary cancer care team for in-depth discussion about current topics and technologies for breast cancer care. The poster will be presented to registered attendees in-person and online. Abstracts will be published online following the conference in the journal Oncology.

"The Miami Breast Cancer Conference is run by leaders in breast cancer care from every oncology specialty," commented Richard Carreon, Managing Director and CEO of ImpediMed. "This is the ideal venue to present the new data evaluating SOZO to assess changes in bone in cancer patients during and after treatment. We continue to stay focused on lymphedema in the near term while exploring new ways to use SOZO in caring for cancer patients as part of our long-term oncology growth strategy."

Expanding the use of SOZO to help care for cancer patients is central to ImpediMed’s growth strategy in the oncology marketplace. Lymphedema provides a strong entry point for adoption of SOZO into oncology practices. Developing new indications creates opportunity to expand SOZO utilization by placing additional SOZO devices and adding new licenses to existing devices. New indications also support the strategy for building large corporate accounts, many of which have interest in co-development and regulatory clearance for new ways to use SOZO to benefit their cancer patients and improve health economics.

There are 16.9 million cancer survivors in the US and approximately 32 million worldwide. The majority of survivors are women with early-stage breast cancers and men with nonmetastatic prostate cancers. These patients frequently receive hormonal manipulation therapies that can significantly impact their bone mineral content. These patients have a higher risk bone fractures potentially leading to hospitalization and death.

About SOZO Digital Health Platform

SOZO, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed’s BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

On February 15, 2022 Paige, the global leader in AI-based diagnostic software in pathology, and Mindpeak, the European leader for AI-based software for image analysis in pathology, reported a distribution partnership, which will enable pathologists to use Mindpeak’s BreastIHC* within the Paige Platform (Press release, Paige AI, FEB 15, 2022, View Source [SID1234608158]). Mindpeak’s BreastIHC is an AI software that reliably and accurately detects, classifies and quantifies breast cancer cells. This partnership enhances the utility of the Paige Platform by providing real-time results for routine breast cancer immunohistochemistry (IHC) biomarkers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The detection and quantification of IHC markers is an important step in treatment planning for breast cancer. Mindpeak’s BreastIHC is the first-ever plug-and-play AI solution for reliable HER2, Ki-67, estrogen (ER) and progesterone receptor (PR) quantification, without the need for complex set-up and calibration procedures. The product helps to differentiate between tumorous and non-tumorous structures on a single-cell basis, improving the specificity of the scoring.

"By combining MindPeak’s products for IHC with Paige’s AI products for H&E, our partnership will allow pathologists to drive efficient routine clinical cancer diagnostics in breast cancer," said Andy Moye, Ph.D., Chief Executive Officer at Paige. "We are excited to offer Mindpeak’s industry-leading BreastIHC directly within the Paige Platform to improve patient care. We believe integrating our products will drive the adoption of digital pathology technologies more broadly."

Paige Platform is a comprehensive digital pathology software platform that is inclusive of a viewer and storage capabilities and is compatible with existing digital pathology solutions, including most scanners, monitors, and laboratory information systems (LIS).

"This partnership brings us a big step closer to our shared goal of making pathological diagnosis of breast cancer quicker, more accurate and more reproducible," said Felix Faber, CEO at Mindpeak. "I am extremely excited that we will combine our respective strengths in analyzing H&E and IHC-stained tissue samples to make this vision of utilizing AI within pathology a reality."

* Mindpeak’s BreastIHC is available in the EU as a CE-IVD marked medical device. Outside the EU, BreastIHC is Research Use Only, not for use in diagnostic procedures.

On February 15, 2022 OncoBeta GmbH reported that the first patients have registered into the world-first International Registry that is capturing data-driven treatment results for NMSC treatments (Press release, OncoBeta, FEB 15, 2022, View Source [SID1234608156]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first-of-its kind International Registry was launched by OncoBeta via specialist health solutions partner Avion Medical in November 2021 to collect real-world patient data for three mainstay treatments of NMSC. Its goal is to identify optimal methods of treating the disease that can be applied internationally.

The International Registry is an easy-to-use platform for physicians and will capture data observing how treatments and innovative approaches influence long-term patient outcomes. The Registry also has an important focus on patient-reported outcomes such as quality of life and comfort of treatment.

The first patients have been recorded into the online registry that follows the treatment journey, from the initial disease assessment to treatments and ongoing assessments. Not only that, but there is an opportunity for patients to contribute their feedback and record their experiences via a questionnaire that includes impact on quality of life as well as comfort score through the OncoBeta WeBe mobile app.

Dr Gerhard Dahlhoff, Medical Director at OncoBeta, says, "To date, no unified reportage on NMSC and its treatments is available to the international medical community. The Registry aims to rectify this shortfall in our understanding of the disease treatment. The WeBe app has been designed so it is easy to use for the patient and the physician, which is critical in ensuring participation and the delivery of robust data. The patient data collection will provide key insights from the patient’s perspective about their treatment and the disease."

An international committee made up of multi-disciplinary clinicians from South Africa, Australia, Italy and Germany is leading the data collection and outputs of the registry. Paolo Castellucci, Nuclear Medicine Physician at S. Orsola, Bologna, and chairman of the International Registry, says, "I’m excited to be involved in an International Registry that will be the first to capture robust, long-term data that will reveal patterns of care, identify which treatment provides the best long term outcomes for patients."

Shannon D Brown III, CEO at OncoBeta GmbH, says, "We are thrilled to see the first patients being registered in the International Registry. By working with clinicians around the world, the Registry will draw from a larger sample size to identify important insights and establish best practices in the treatment of NMSC."

Participation in the International Registry for Non-Melanoma Skin Cancer Treatment is by invitation only. Physicians that would like to become part of the Registry and offer Rhenium-SCT treatment at your centre, contact [email protected]

About the Rhenium-SCT (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans. The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.1

The Rhenium-SCT is a painless*, single session†, non-invasive therapy providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat.2-4 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient’s skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session†4. Scar-free healing4 of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment4.

On February 15, 2022 Medivir reported that Year-End Report, January – December 2021 (Press release, Medivir, FEB 15, 2022, View Source;year-end-report-january–december-2021-301482292.html [SID1234608155])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

October – December

Financial summary for the quarter

Net turnover amounted to SEK 13.9 (1.5) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -23.5 (-10.6) million. Basic and diluted earnings per share amounted to SEK -0.44 (-0.46) and SEK -0.44 (-0.46) respectively.
Cash flow from operating activities amounted to SEK -5.4 (-1.0) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 221.2 (70.0) million.
Significant events during the quarter

In October, the Board of Directors appointed Jens Lindberg as new CEO of Medivir. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial Operations and acting CEO.
IGM Biosciences, Inc. initiated its clinical study in solid cancers with birinapant (IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The purpose of this first clinical trial with the combination is to evaluate safety and tolerability.
In November, results from an investigator-initiated phase II clinical trial of remetinostat in patients with squamous cell carcinoma were published.
In December, it was announced that the first patient with hepatocellular carcinoma had started treatment with fostroxacitabine bralpamide (MIV-818) in the phase 1b / 2a combination study.
January – December

Financial summary for the period

Net turnover amounted to SEK 25.5 (13.9) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -59.5 (-38.5) million. Basic and diluted earnings per share amounted to SEK -1.20 (-1.75) and SEK -1.20 (-1.75) respectively.
Cash flow from operating activities amounted to SEK -48.7 (-58.1) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 221.2 (70.0) million.
Significant events after the end of the period

In January, it was announced that the WHO had selected fostroxacitabine bralpamide as the official generic name for the patented candidate drug MIV-818, which is in clinical development in primary liver cancer.
Jens Lindberg assumed his position as CEO of Medivir on January 24, 2022.
Conference call for investors, analysts and the media

The Year-End Report January – December 2021 will be presented by Medivir’s CEO, Jens Lindberg.

The conference call will also be streamed via a link on the website: www.medivir.com

The presentation will be available on Medivir’s website after completion of the conference.

CEO’s message

On January 24, 2022, I took over as CEO of Medivir and after my first time on the job, it is clear to me why the company managed to deliver so well on business goals in 2021. We have an extremely competent and experienced team that works dedicatedly with both our cutting-edge project fostroxacitabine bralpamide (MIV-818) and with the business development for our other assets. I hope to be able to contribute to the further strengthening of our delivery capacity in the future. Under the leadership of the company’s former CEO Yilmaz Mahshid, today a board member of Medivir, and our CFO Magnus Christensen, who has been the company’s interim CEO since May, Medivir has made significant progress in 2021.

Medivir’s drug development focuses on a very promising and proprietary clinical project, fostroxacitabine bralpamide (formerly MIV-818), with a clear therapeutic target, where the unmet medical needs remain extremely large, despite recent clinical advances. Fostroxacitabine bralpamide has the potential to become the first liver-targeted and orally administered drug that can help patients with various cancers of the liver. Its unique mechanism of action means that it does not directly compete with other treatment options but instead enables combination treatments with other drug alternatives in hepatocellular carcinoma (HCC). Liver cancer is the third leading cause of cancer-related deaths worldwide and HCC is the most common form of cancer that arises in the liver. The effect of today’s medications is often limited and mortality remains at a high level.

After the end of the year, MIV-818 received the official generic name fostroxacitabine bralpamide from the World Health Organization WHO, something we see as an important step towards a product for the treatment of HCC.

The clinical development program for fostroxacitabine bralpamide has passed a number of milestones during the year. In April, it was announced that the top-line results from the monotherapy part of the phase Ib study were positive with a good safety and tolerability profile. They were later presented in more detail at the ESMO (Free ESMO Whitepaper) Congress in September and aroused great interest. In May, the design for the next step, the phase 1b/2a combination study with fostroxacitabine bralpamide for liver cancer, was presented. The regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for the study was obtained at the end of August, and from the South Korea Ministry of Food and Drug Safety (MFDS) in November.

In December, the first patient with HCC was dosed in the phase 1b/2a combination study with fostroxacitabine bralpamide, which is given in combination with two other medicines, either with Lenvima, a tyrosine kinase inhibitor, or with Keytruda, an anti-PD-1 checkpoint inhibitor. Lenvima and Keytruda (approved in the USA) are currently approved as mono therapy treatments of HCC.

The licensing agreement with IGM Biosciences, Inc., which gives IGM the global and exclusive rights to develop birinapant, could potentially provide milestone payments up to a total of approximately USD 350 million as well as tiered royalties up to "mid-teens". At the time of signing in January 2021, Medivir received USD 1 million, and when IGM in early November initiated a phase I clinical trial in solid cancers with birinapant in combination with its own DR5 agonist antibody IGM-8444, it was followed by an additional USD 1.5 million. Of course, we look forward to IGM’s continued clinical development of birinapant.

Also for remetinostat, a number of steps forward made during the year should be noted. Positive results from the investigator-initiated phase II clinical trial of remetinostat in patients with squamous cell carcinoma were published in November in the scientific journal JAMA Dermatology. Promising results from the investigator-initiated phase II study with remetinostat for basal cell carcinoma were published in August in the scientific journal Clinical Cancer Research. Through a renegotiated multi-party agreement, Medivir was able to further strengthen the business development potential for remetinostat in August.

Business development and collaborations are central to Medivir’s success. Birinapant is a good example of this and we see opportunities for remetinostat and MIV-711, but also in other smaller projects. In early 2021, a licensing agreement was entered into with Ubiquigent for the preclinical research program USP7.

Thanks to the financing that was successfully carried out at the beginning of the year and provided the company with approximately SEK 223 million before transaction costs, we are entering 2022 with resources and business development opportunities that provide good conditions for continuing the clinical development program for our cutting-edge project fostroxacitabine bralpamide. Our goal is to make it an effective drug for liver cancer that makes a real difference for patients and for healthcare, and thus also for our shareholders. I look forward to keeping you informed about Medivir’s continued development.